News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
-being-attacked-by-two-cytotoxic-t-cells-(red)-547x410.tmb-hbmobile.png?Culture=en&sfvrsn=8f59440b_2 "Immunotherapy - Oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red) 547x410")
ESMO 2021: Immunotherapy combination could be alternative to ‘Extreme’ chemotherapy in some head and neck cancers
An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.
.jpg?sfvrsn=2f49a1c2_2 "HRH visit plaque unveiling (high res)")
The Princess Royal officially opens pioneering centre for 'Darwinian' cancer drug discovery
Her Royal Highness The Princess Royal has officially opened the Centre for Cancer Drug Discovery and toured the centre to learn more about its work to overcome cancer’s ability to evolve and become resistant to treatment.
'Gut bugs' can drive prostate cancer growth and treatment resistance
Common gut bacteria can fuel the growth of prostate cancers and allow them to evade the effects of treatment, a new study finds.
Scientists use AI to identify new drug combination for children with incurable brain cancer
Scientists have used artificial intelligence-enhanced tools to successfully propose a new combination of drugs for use against an incurable childhood brain cancer.
ESMO 2021: Drug combination shows promise in treatment-resistant advanced ovarian cancer
A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.
ESMO 2021: Abiraterone keeps men with prostate cancer at risk of spreading alive for longer
Giving the drug abiraterone alongside standard hormone therapy helps men with high-risk prostate cancer, that has not spread elsewhere in the body, live longer.
Shorter radiotherapy courses for prostate cancer are well tolerated long-term by patients
A shorter course of radiotherapy, administered through fewer, higher intensity doses, is as well tolerated over five years as longer treatment courses for treating prostate cancer, long-term results of a clinical trial show.
Monte Rosa Therapeutics lists on New York Stock Exchange
Monte Rosa Therapeutics, a biotechnology company originally formed as a spinout from science at The Institute of Cancer Research, London, partly funded by Cancer Research UK, is now listed on the Nasdaq stock exchange in New York.
Cancer vaccine could be effective way to overcome treatment resistance
A cancer vaccine could be an effective way to prevent cancer from evolving and becoming resistant to treatment, new research suggests.
ICR comes top in university invention income for eighth successive year
The Institute of Cancer Research, London, has earned the most staff-adjusted invention income of any UK higher education institution for the eighth year in a row.
Shorter course of radiotherapy safely delivers treatment for prostate cancer
Advanced radiotherapy technology can safely deliver curative treatment for prostate cancer patients in as few as five sessions, with only minimal side effects, according to new research from The Royal Marsden NHS Foundation Trust and the ICR.
-547x410.jpg?sfvrsn=5e98f2c_2 "Clinical trials pharmacy (Jan Chlebik for the ICR, 2014) 547x410")
Innovative ICR-discovered drug to enter first clinical trial, targeting HSF1 pathway
Cancer patients are set to receive, for the first time, a highly innovative investigational drug called NXP800 – which was discovered at The Institute of Cancer Research, London.
